# Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)

> **NCT05650164** · — · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 171 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** avelumab
- **DRUG:** axitinib

## Key facts

- **NCT ID:** NCT05650164
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-25
- **Primary completion:** 2023-10-13
- **Final completion:** 2023-10-13
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2025-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05650164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05650164, "Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05650164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*